Xarelto Lawyers at Bernstein Liebhard LLP Comment on Study Examining Use of Novel Anticoagulants Among ICU Patients

Share Article

The study comes as dozens of plaintiffs, including a number being represented by the Firm, pursue Xarelto lawsuits after allegedly suffering uncontrollable bleeding and other complications due to the blood thinning medication.

Free Case Review
This study is of interest to our Firm, as we are representing a number of individuals in Xarelto lawsuits who allegedly suffered uncontrollable internal bleeding due to the use of this medication.

The Xarelto lawyers (http://www.xareltolawsuit2015.com/xarelto-lawyer/) at Bernstein Liebhard LLP note with interest the release of a new study examining the use of novel anticoagulants in the ICU. According to an abstract published in the December 2014 issue of Critical Care Medicine, 21 ICU patients were included in the study. Nine of those individuals were treated with rivaroxaban, which is currently sold under the brand name Xarelto. Five received dabigatran (Pradaxa), while seven where treated with apixaban (Eliquis).*

The authors of the study raised a number of issues, including the lack of a reversal agent to stop internal bleeding that is sometimes associated with the use of these medications. Among other things, they noted that treating physicians did not take kidney problems suffered by four patients into account when dosing the drugs. One of those patients experienced internal bleeding. The authors determined that there is a lack of experience with the use of novel anticoagulants in critically ill patients, and concluded that this is an area that needs further study.

“This study is of interest to our Firm, as we are representing a number of individuals in Xarelto lawsuits who allegedly suffered uncontrollable internal bleeding due to the use of this medication. Among other things, these lawsuits also raise the issue of a lack of a reversal agent for Xarelto bleeding,” said Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free, no-obligation Xarelto case reviews to people who allegedly suffered serious injuries from the blood thinner, including uncontrollable bleeding, strokes, deep vein thrombosis or pulmonary embolism.

Xarelto Lawsuit Allegations
Xarelto (rivaroxaban) was approved by the U.S. Food & Drug Administration in 2011, and is currently indicated to prevent strokes in people with atrial fibrillation; as a treatment for deep vein thrombosis and pulmonary embolism; and to prevent deep vein thrombosis in patients undergoing hip or knee replacement surgery. Like all blood thinners, Xarelto can sometimes cause patients to experience internal bleeding. However, no antidote has yet been approved for Xarelto bleeding.**

Court documents indicate that dozens of federally-filed Xarelto lawsuits have been consolidated in a multidistrict litigation now underway in the U.S. District Court, all of which have been filed on behalf of individuals who allegedly experienced uncontrollable internal bleeding and other dangerous side effects due to their use of Xarelto. Among other things, these lawsuits allege the drugs’ manufacturers wrongly marketed Xarelto as a superior alternative to warfarin, a blood thinner that has been on the market for decades. Plaintiffs point out that while there is no approved antidote to reverse Xarelto bleeding, warfarin bleeding can be reversed via the administration of vitamin K. (In Re: Xarelto Products Liability Litigation, No. 2592)

Xarelto patients who allegedly suffered serious episodes of internal bleeding and other complications related to its use may be entitled to compensation for their medical bills, lost wages, pain and suffering and more. Find out more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP’s website, or by calling 800-511-5092 to schedule a free, no obligation case review.

*journals.lww.com/ccmjournal/Citation/2014/12001/463___EVALUATION_OF_THE_USE_OF_NOVEL_ORAL.430.aspx, Critical Care Medicine (Abstract #463), December 2014
**fda.gov/downloads/Drugs/DrugSafety/UCM280333.pdf, FDA, March 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website